Good news: An FDA committee recently voted in favor of MannKind Corporation (NASDAQ:MNKD)’s new inhaled insulin for diabetes sufferers. The biopharmaceutical company’s latest advancement in diabetes treatments passed the panel’s inspection, but will this translate into FDA approval? While some analysts are focused on the new drug’s potential and are eager to recommend BUY MannKind, other analysts are concerned about FDA restrictions and only recommend HOLD MannKind. MannKind Corporation (NASDAQ:MNKD) stock opened today at $7.00 and is currently trading at $6.95. The stock showed a positive weekly performance of 33.27%.
Gilead Sciences, Inc. (NASDAQ:GILD), research based pharmaceutical company, announced positive results for a pivotal study of its drug sofosbuvir for treatment of Japanese patients diagnosed with a common form of the hepatitis C virus. The Foster city, California based medicine producer said on Wednesday that it seeks to file for a regulatory approval of the pill, sold under the brand name of Sovaldi in the U.S., in Japan, by the middle of 2014. Gilead had been in news for its drug Sovaldi in the U.S. in March when the country’s lawmakers had questioned the high costs of the drug. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened at $74.91, in current trading session and currently is at $74.36, by gaining 0.47%. The 52 week range of $46.53-$84.88. Company’s market capitalization is $114.40 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) Insider Timothy P. Clackson sold 6,500 shares of Ariad Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $8.21, for a total value of $53,365.00. Following the transaction, the insider now directly owns 403,028 shares in the company, valued at approximately $3,308,860. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock is currently trading at $-0.51 .The EPS of the stock is -1.49. Company’s market capitalization is $1.44 billion.
On Thursday, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has confirmed the pricing of its earlier announced underwritten public offering of its 11,325,000 shares of common stock. For the issue of the shares with par value of $0.001 per share, the company has entered into an underwriting agreement with Piper Jaffray & Co. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock opened the session at $2.39, and now is at $2.42. The 52 week range of the CPRX stock remained $0.45-$3.65 and the day range was $2.38-$2.49.
Leave a Reply